Reviews/Osteoporosis Fracture Prevention/Romosozumab versus alendronate fracture risk
Anabolic And Sequential Therapy · ostfrac_08 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
One large, blinded, high-quality head-to-head trial [1] directly compared romosozumab against alendronate in postmenopausal women with osteoporosis and found fewer vertebral, clinical, nonvertebral and hip fractures in the romosozumab group. Several further analyses of the same trial population [2],[5],[8],[9] point in the same direction, and bone-strength measurements [10] line up with that fracture finding. The main hesitation is that almost all the fracture evidence comes from this one trial rather than being reproduced in separate studies. The trial also gave both groups alendronate after the first year, so part of the later difference reflects the treatment sequence rather than a pure drug-versus-drug comparison. The tested patients were all postmenopausal women already at high fracture risk, so the finding cannot be assumed to extend to men or lower-risk patients. The panel judged the direct evidence strong but stopped short of the top tier because it leans so heavily on a single trial.
The pivotal head-to-head RCT [1] enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and reported a 48% lower risk of new vertebral fracture (6.2% vs 11.9%, P<0.001), a 27% lower risk of clinical fracture (P<0.001), a 19% lower risk of nonvertebral fracture (P=0.04) and a 38% lower risk of hip fracture (P=0.02) with romosozumab-to-alendronate versus alendronate alone. Post hoc and subgroup analyses of the same ARCH cohort are concordant: the East Asian subgroup [2] showed 60% and 44% reductions (non-significant, P=0.11 and P=0.15), the CKD subgroup [5] showed vertebral reductions by eGFR band in ARCH, on-study fracture analyses [8] were numerically lower, and the T-score analysis [9] reported a 75% year-2 vertebral reduction (P<0.001) with 19% nonvertebral (P=0.120) and 40% hip (P=0.041). Bone-strength and microarchitecture surrogates [6],[10],[11] consistently favour romosozumab over alendronate. The placebo-controlled FRAME trial [7] establishes efficacy versus placebo but does not compare against alendronate. The contested point: The division is over evidential independence: nearly all head-to-head fracture evidence traces to the single ARCH cohort [1], and [2],[5],[8],[9] are post hoc re-analyses of that same 4093-patient population rather than independent replications. A secondary tension is that ARCH is a romosozumab-to-alendronate sequence versus alendronate-alone design, so later separations partly reflect the sequence rather than a sustained direct comparison.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Almost all head-to-head fracture evidence derives from a single trial (ARCH); [2],[5],[8],[9] are post hoc re-analyses of the same 4093-patient cohort, not independent replications, so evidential independence is weak.
ARCH is a romosozumab-to-alendronate sequence vs alendronate-alone design; later separations partly reflect the sequence rather than a sustained head-to-head romo-vs-alendronate comparison.
Where it remains uncertain. Almost all fracture evidence derives from the one ARCH cohort; [2],[5],[8],[9] re-analyse the same patients and several subgroup reductions are non-significant [2] (P=0.11, 0.15), [9] (P=0.120).
Aleatory
Small subgroup samples [2] (N=275) yield non-significant estimates (P=0.11, 0.15) that corroborate direction only.
Epistemic
Almost all head-to-head fracture evidence is the one ARCH cohort [1]; [2],[5],[8],[9] re-analyse the same patients with no independent replication.
Inferential
Papers [6],[10],[11] report BMD, bone-strength and microarchitecture, not fracture outcomes, so they support the mechanism but cannot by themselves carry a fracture-risk claim.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal powered head-to-head RCT establishing significant vertebral fracture superiority over alendronate.
“Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001).”
Panel auditInternal validity: high · scope of inference: Postmenopausal women with osteoporosis and a prior fragility fracture at high risk, over 24 months.Key limitations: both arms transitioned to alendronate so effect is of the sequence · more serious cardiovascular events with romosozumab in year 1
East Asian subgroup: consistent direction, though non-significant and underpowered.
“Romosozumab followed by alendronate reduced risk of new VFs at 24 months by 60% (P = 0.11) and clinical fractures at primary analysis by 44% (P = 0.15) vs alendronate alone.”
Panel auditInternal validity: medium · scope of inference: High-risk postmenopausal East Asian women from Hong Kong, Korea and Taiwan within ARCH.Key limitations: small underpowered subgroup · non-significant fracture p-values · post hoc analysis
CKD subgroup of ARCH showing vertebral-fracture reductions vs alendronate across kidney-function bands.
“and by 51% (5-75; p = 0.04), 19% (-28 to 49; p = 0.39), and 57% (1-81, p = 0.04), respectively, in ARCH versus alendronate.”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women with osteoporosis and mild-to-moderate CKD, vertebral fracture at month 12.Key limitations: post hoc subgroup · mixes FRAME placebo contrast with ARCH alendronate contrast · middle eGFR stratum non-significant
The abstract reports only DXA-derived BMD and structural parameters; fracture is mentioned only as a downstream rationale, not measured.
Panel auditInternal validity: medium · scope of inference: Subset of ~185 per group with total-hip DXA, bone density and structure at 12 and 24 months.Key limitations: BMD/structure surrogate not fracture · consent-selected subset · post hoc
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One large, blinded, powered superiority RCT carries the claim directly, but single-trial dependence and subgroup non-significance warrant a conservative Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent head-to-head replication. All direct fracture evidence derives from the single ARCH cohort [1], with [2],[5],[8],[9] re-analysing the same patients. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A separate, adequately powered, blinded romosozumab-versus-alendronate RCT with fracture endpoints in an independent population.
Open question: Does romosozumab's fracture-risk superiority over alendronate replicate in an independent, powered head-to-head trial? Why it is still open: All direct fracture evidence in the corpus is the single ARCH trial [1] and its post hoc re-analyses [2],[5],[8],[9].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19